Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Legal · Privacy

Privacy Policy

Privacy Policy describing what US Telehealth Review collects, how it's used, and GDPR/CCPA rights for readers — first-party only, no third-party ad cookies, no data sales.

Published by Ranika Editorial Group LLC Last updated 2026-06-19

This Privacy Policy describes what information US Telehealth Review collects, how it is used, and the reader's rights under the General Data Protection Regulation (GDPR), the California Consumer Privacy Act (CCPA), and other applicable privacy laws. Last updated 2026-06-19.

1. Information we collect

Automatically collected:

  • Device and browser information (user agent, screen size, language).
  • Page URLs visited, time on page, referrer URL.
  • Approximate geographic location derived from IP address (country, region, city — not street address).
  • Anonymous behavioral analytics through privacy-respecting analytics platforms.

Voluntarily provided:

  • Email address when the reader submits a correction request, tip, complaint, or subscribes to editorial updates.
  • Free-text content of the reader's submission.

We do not require account creation to read any page on US Telehealth Review. We do not collect Social Security numbers, payment card information, medical history, or any other sensitive personal information.

2. How we use information

  • To respond to reader emails and process correction requests.
  • To send editorial updates and pricing alerts only when the reader explicitly subscribes.
  • To improve editorial content based on aggregate, anonymous traffic patterns.
  • To detect and prevent abuse, fraud, and security incidents.
  • To comply with legal obligations including subpoenas and lawful government requests.

3. Cookies and tracking

We use first-party cookies for essential site functionality and aggregate analytics. We do not use third-party advertising cookies, do not sell behavioral data, and do not participate in real-time bidding ad networks. Affiliate-link tracking parameters (utm_source, utm_medium, utm_campaign, utm_content) are appended to outbound links so providers can attribute referrals; these parameters do not include any reader-identifying information.

4. Sharing with third parties

We do not sell reader data. We share information only:

  • With service providers (email infrastructure, analytics, content delivery network) bound by confidentiality and data-protection contracts.
  • When required by law or to protect against fraud, security threats, or violations of our terms of use.
  • In connection with a merger, acquisition, or sale of Ranika Editorial Group LLC, in which case the acquirer assumes the obligations of this policy.

5. Your rights

Under the GDPR (EU/UK readers): the right to access, correct, delete, restrict, and port personal data, and to object to processing. To exercise these rights, email privacy@ustelehealthreview.com. We respond within 30 days.

Under the CCPA/CPRA (California readers): the right to know what personal information is collected, the right to delete personal information, the right to opt out of sale (we do not sell), and the right to non-discrimination for exercising these rights. To exercise these rights, email privacy@ustelehealthreview.com.

For all readers worldwide, we honor reasonable data-deletion requests within 30 days of verification.

6. Children

US Telehealth Review is not directed at children under 16. We do not knowingly collect information from anyone under 16. If a parent or guardian believes a child has submitted information to us, please contact privacy@ustelehealthreview.com for immediate deletion.

7. Data retention

Reader-submitted emails are retained for two years from last contact, then automatically deleted unless retention is required for an active correction, legal matter, or the reader has subscribed to ongoing editorial updates. Aggregate, de-identified analytics are retained indefinitely.

8. Security

We use TLS encryption for all site traffic, restrict employee access to reader data on a least-privilege basis, and maintain incident-response procedures. No method of transmission over the internet is 100% secure; we do not guarantee absolute security but we work to protect reader information using commercially reasonable safeguards.

9. Changes to this policy

Material changes to this Privacy Policy will be flagged at the top of this page for at least 30 days before taking effect. Continued use of the site after a change constitutes acceptance of the revised policy.

10. Contact

Privacy questions, data-access requests, and complaints can be sent to privacy@ustelehealthreview.com or by mail to Ranika Editorial Group LLC, Attn: Privacy, 1209 Orange Street, Wilmington, DE 19801, United States.

Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
Editor
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing